Gene therapy research from CANbridge-UMass Chan Medical School to be presented at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

First study from the CANbridge UMass Chan Medical School Rare Disease Gene Therapy Research Collaboration

BEIJING AND CAMBRIDGE, MA, May 04, 2022–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., (“CANbridge”, 1228.HK), a leading global biopharmaceutical company based in China and engaged in the research, development and commercialization of transformative therapies for rare diseases and oncology rare, announced that data from its gene therapy research agreement with the Horae Gene Therapy Center, at UMass Chan Medical School, will be presented at ASGC 25and Annual meetingtaking place in Washington DC May 16-19and. The researchers will present the results of an animal study exploring a novel second-generation gene therapy for the potential treatment of spinal muscular atrophy (SMA). This is the first data from the CANbridge Rare Disease Gene Therapy Research Collaboration with UMass Chan Medical School, which focuses on developing gene therapy treatments for neuromuscular diseases with unmet medical needs.

Presentation details:

Title: Endogenous Human SMN1 Promoter-Induced Gene Replacement Improves Efficacy and Safety of AAV9-Mediated Gene Therapy for Spinal Muscular Atrophy in Mice

Poster #: M-144

Category: Neurological diseases I

Date and time of the session: Monday, May 16, 5:30-6:30 p.m.
Authors:
Qing Xie, Hong Ma, Xiupeng Chen, Yunxiang Zhu, Yijie Ma, Leila Jalinous, Qin Su, Phillip Tai, Guangping Gao, Jun Xie

The summaries are available on the ASGCT website: https://annualmeeting.asgct.org

About UMass Chan Medical School Horae Gene Therapy Center

The faculty of the Horae Gene Therapy Center is dedicated to developing therapeutic approaches for rare inherited diseases for which there is no cure. We use state-of-the-art technologies to either genetically modulate mutated genes that produce disease-causing proteins, or introduce a healthy copy of a gene if the mutation results in a non-functional protein.

The faculty at the Horae Gene Therapy Center is interdisciplinary and includes members from the departments of Pediatrics, Microbiology and Physiological Systems, Biochemistry and Molecular Pharmacology, Neurology, Medicine, and Ophthalmology. Physicians and doctors work together to meet the medical needs of rare diseases, such as alpha 1-antitrypsin deficiency, Canavan disease, Tay-Sachs and Sandhoff diseases, retinitis pigmentosa, cystic fibrosis, Lou Gehrig’s disease, TNNT1 nemaline myopathy, Rett’s syndrome, N-Gly 1 deficiency, Pitt-Hopkins syndrome, Marple syrup urinary disease, sialidosis, GM3 synthase deficiency, Huntington’s disease, ALS and others . More common diseases such as cardiac arrhythmia and hypercholesterolemia are also studied. The hope is to treat a wide range of diseases by various gene therapy approaches. In addition, the Chan Medical School at the University of Massachusetts organizes on-site clinical trials and some of these trials are conducted by researchers at the gene therapy center.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (“CANbridge”, 1228.HK) is a China-based global biopharmaceutical company focused on rare diseases and engaged in the research, development and commercialization of transformative therapies for rare diseases and rare oncology.

CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology.

These include Hunter syndrome (MPS II) and other lysosomal storage disorders (LSD), complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases including syndrome d’Alagille (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA) as well as glioblastoma multiforme (GBM).

CANbridge strategically combines global collaborations and internal research to grow and diversify its drug portfolio and invest in next-generation gene therapy technologies for the treatment of rare diseases. CANbridge Global Partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, University of Massachusetts Chan School of Medicine, University of Washington School of Medicine, LogicBio and Scriptr.

To learn more about CANbridge Pharmaceuticals Inc., please visit: www.canbridgepharma.com.

Forward-looking statements

Forward-looking statements made in this article relate only to events or information as of the date the statements are made in this article. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, following the data on which the statements are made or to reflect the occurrence of unforeseen events. events. You should read this article in its entirety and be aware that our actual future results or performance may differ materially from what we expect. In this article, statements or references to our intentions or those of any of our directors or our company are made as of the date of this article. Each of these intentions may change in light of future development.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220503005199/en/

contacts

Relations with American investors:
Chris Brinzey
ICR Westwicke
[email protected]

China Investor Relations
CANbridge Pharmaceuticals Inc.
[email protected]

Media:
Deanne Eagle
Planet Communications
[email protected]
917.837.5866

Comments are closed.